|
|
 |
|
Viewing report
|
|
|
|
Mucopolysaccharidosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017
GlobalData, July 2011, Pages: 62
Mucopolysaccharidosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, “Mucopolysaccharidosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global mucopolysaccharidosismarket. The report identifies the key trends shaping and driving the global mucopolysaccharidosismarket. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global mucopolysaccharidosis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData’s analysis revealed that the global Mucopolysaccharidosis (MPS) market was worth $0.65 billion in 2010. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 9.6% for the next seven years, to reach $1.24 billion by 2017. This is primarily attributed to the increase in the prevalence of the disease and pipeline molecules targeting the MPS subtypes where there were no approved treatment options available. A weak clinical pipeline coupled with high unmet need in the MPS therapeutics market will lead to the steady growth in the market.
Scope
The report provides information on the key drivers and challenges of the mucopolysaccharidosis market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) mucopolysaccharidosismarket revenues data from 2005 to 2010, forecast for seven years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. The pipeline products are also enzyme replacement therapies, but indicated for the treatment of MPS IV, III and II.
- Analysis of the current and future competition in the seven key countries mucopolysaccharidosis market. Key market players covered are BioMarin Pharmaceuticals Inc. and Shire Plc.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the mucopolysaccharidosis therapeutics market.
- Analysis of key recent licensing and partnership agreements in mucopolysaccharidosis market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global mucopolysaccharidosis market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global mucopolysaccharidosis market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global mucopolysaccharidosis market landscape? – Identify, understand and capitalize.
|
|
|
|
